Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arcitumomab
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Arcitumomab is a murine monoclonal antibody Fab' fragment that targets carcinoembryonic antigen (CEA), a protein overexpressed in the majority of colorectal cancers. It is used as a radiopharmaceutical diagnostic agent when labeled with technetium-99m (as Technetium Tc-99m arcitumomab or CEA-Scan) for imaging and detection of colorectal cancer lesions. The Fab' fragment binds selectively to cell-surface CEA on tumor cells; after radiolabeling with technetium-99m, it accumulates in tumors and enables high-resolution imaging via single photon emission computed tomography (SPECT). This allows clinicians to localize primary and metastatic lesions, assess remission or progression, and monitor for recurrence following resection[1][5][6][7].
- Brand names
- CEA-Scan
- Other names
- Technetium Tc-99m arcitumomab99mTc-arcitumomab
Beyond the preview
Go deeper on arcitumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arcitumomab.